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In this study, it was aimed to develop, characterize, and improve the antioxidant activity of gallic acid (GA) by 
formulating it into microemulsion (ME) and microemulsion gel (MEg). Blank MEs were prepared using different 
proportions of oil/water/surfactant, which provide stable and transparent ME production. Their droplet sizes, zeta potentials 
and stabilities after holding, centrifugation, and freeze-thawing processes were determined. F2 and F5 coded MEs were 
selected among the blank MEs and GA was loaded into these formulations. Besides the characterization studies, pH and 
viscosity measurement, in vitro release, cytotoxicity test, cell permeation, and antioxidant activity studies were performed. 
In vitro released amount of GA was enhanced by formulating it into ME and MEg at the end of six hours and it showed a 
scavenging effect of DPPH● and ABTS●+ radicals. In conclusion, increased efficacy, reduced toxicity, and prolonged 
antioxidant activity have been achieved with the use of new, non-toxic, and stable ME and MEg loaded with GA and it is 
thought that these formulations create the potential for topical application. 
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Introduction 
Microemulsions (MEs) are transparent or translucent 
thermodynamically stable systems with a droplet size of 
20-200 nm, mainly containing oil, water, surfactant, and 
usually contains a co-surfactant. MEs are characterized 
by very low interfacial tension between oil and water 
phases and classified as water-in-oil (w/o), oil-in-water 
(o/w) or bicontinuous systems1,2. For the formation of 
low viscosity, transparent, and stable ME, the use of 
appropriate surfactant and co-surfactant in ideal 
proportions is important by causing an interface pressure 
that exceeds the interfacial tension at the oil-water 
interface3. Human skin, the external part of the body, 
prevents penetration of drugs as it acts as a barrier 
against different factors such as ultraviolet radiation, 
toxic substances, and microorganisms4. MEs are 
promising for topical and transdermal administration 
of both hydrophilic and lipophilic drugs as they 
improve the solubility, absorption, and permeation rate 
and hence the therapeutic effect of the drugs due to 
their unique formulation properties, thermodynamic 
stability, excellent biocompatibility, and hydrophilic & 
lipophilic fields5-7. MEs increase drug solubility by 
increasing the solubility of the drug, increasing the 
thermodynamic activity of drugs, the permeability 
enhancing effects of the formulation components and the 
hydration effect of MEs on the stratum corneum8. 
Microemulsion gels (MEgs) are prepared by the 
combination of MEs with bioadhesive gel such as 
Carbopol to increase contact time of the formulation 
with skin by increasing viscosity. 
Gallic acid (3,4,5-trihydroxybenzoic acid) (GA) is a 
lipophilic polyhydroxyphenolic compound commonly 
found in many different plant families such as 
Anacardiaceae, Fabaceae, and Myrtaceaeas9,10. GA is 
known to have antibacterial, antiviral, antifungal, anti-
inflammatory, antioxidant and prooxidative effects11,12. 




Phone: +90352 207 66 66 Fig. 1 — Chemical structure of gallic acid. 




Oil-in-water ME is preferred, as it is more suitable 
for delivery of lipophilic drugs4. Therefore, in the 
current study, it was aimed to develop and 
characterize the lipophilic antioxidant GA-loaded oil-
in-water ME and MEg formulations, to evaluate 
cytotoxicity, transport properties through L929 cell 
line and antioxidant activity with using 1,1-diphenyl-
2-picrylhydrazyl (DPPH●) and 2,2′-azino-bis-3-
ethylbenzthiazoline-6-sulphonic acid (ABTS●+) 
radical scavenging activity assays. 
 
Materials and Methods 
 
Materials 
GA (G7384, Sigma, USA), Tween 20 (817072, 
Merck, Germany), Polietilen glikol 400 (PEG400, 
25322-68-3, Loba Chemie, India), Olive oil 
(purchased from the market, Komili, Turkey) and 
Carbopol 980 (purchased from Abdi İbrahim 
Pharmaceutical, Industry and Trade Company, 
Turkey) were used. All other chemicals used were 
analytical grade. L929 cell line was provided from the 
American Type Culture Collection (ATCC® CCL-
1™). Cell culture flasks and cell culture plates 6 well 
(3412, Transwell™) were purchased from Corning®. 
Cedex Smart Slides and Trypan Blue solution were 
purchased from Roche (Switzerland). 
 
Quantification of GA 
UV-spectrophotometer was used to measure drug 
content in ME and MEg. The Maximum spectrums of 
GA were measured from 200 to 550 nm with a 
spectrophotometer (Shimadzu 1800, Japan) and the 
maximum wavelength was found to be 284 nm(ref 13). 
The calibration curve was linear from 40 to 2.5 μg/mL 
with a high correlation coefficient (r2=0.997). A stock 
solution of GA was prepared in aqueous ethanol  
(1:3 v/v) at a concentration of 40 µg/mL and stored in 
the dark. Working solutions were prepared from stock 
solution with dilution down to a final concentration of 
2.5 µg/mL for calibration curves. The standard curve 
was calculated by linear regression, according to the 
following formula: y= ax + b, where x is GA the 
concentration as μg/mL and y is the absorbance at the 
maximum spectrum (284 nm) of GA. 
 
Preparation of MEs and Megs  
The newly developed ME formulations were 
prepared by titration method14. Tween 20: PEG 400 
mixture was added to the oil phase in a 2:1 ratio and a 
constant amount of water was added dropwise by 
stirring continuously in the magnetic stirrer. ME 
formulations were prepared by using different ratios 
of oil, surfactant: cosurfactant mixture and water were 
given in Table 1. 
GA-loaded MEs were prepared using the oil: 
water: surfactant ratios given in Table 1 by adding the 
GA solution in ethanol to the oil phase. GA-loaded 
MEgs were also prepared by using Carbopol 980. 
Gels were first prepared, 1.0% (w/v) of Carbopol 980 
was added to distilled water, adjusted to pH 5.5 with 
triethanolamine in 1:1 (v/v) ratio and allowed to swell 
overnight at room temperature, then, optimized MEs 
(F2 and F5) and gel were mixed in the ratio of 1:1 
(v/v) of 1.0% (w/v) Carbopol 980 solution and GA-
loaded ME. 
 
Characterization of MEs  
In the characterization studies, droplet size (DS), 
zeta potential (ZP), dilution tests, and viscosities of 
developed MEs were measured. In addition, after the 
centrifugation, retention, and freeze-thawing, stability 
of MEs was evaluated. 
DS and ZP of MEs were measured using a  
Malvern Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, United Kingdom) (Table 2). The 
physical appearance of MEs was determined using a 
polarized microscope (Zeiss Primo Star, Germany). 
To determine whether the ME was monophasic or not, 
the MEs were diluted with distilled water to confirm 
the emulsion type and miscibility with the aqueous 
phase. The pH of GA loaded formulations was 
 
Table 1 — Composition of microemulsion formulations 








F1 5 2:1 50 45 
F2 5 2:1 55 40 
F3 7,5 2:1 45 47,5
F4 7,5 2:1 47,5 45 
F5 10 2:1 45 45 
F6 10 2:1 50 40 
 
Table 2 — Droplet size and zeta potential of blank  
microemulsions 
Formulation Droplet size  
(µm±SD) 
Zeta Potential  
(mV±SD) 
F1 1.335±0.02 -20.1±0.2 
F2 1.002±0.01 -33.6±0.3 
F3 2.142±0.04 -13.5±0.2 
F4 2.060±0.05 -21.3±0.4 
F5 1.247±0.02 -35.7±0.4 
F6 1.880±0.03 -21.3±0.3 
Values are expressed as mean±standard deviation, n=3 
 




measured using a Digital pH meter (Mettler Toledo 
Seven Compact, Switzerland). The viscosity was 
measured using spindle number 14 at 10, 20, 50, and 
100 rpm at room temperature (Brookfield Viscometer 
LVDV-I Prime, USA). In addition, the formulations 
were centrifuged at 10.000 rpm for 30 minutes using  
a cold centrifuge (Thermo Scientific, USA), frozen  
at -80 ºC for two hours and dissolved at room 
temperature; and then the system was examined as 
monophasic or biphasic15. The stability of ME 
formulations was also investigated at 4 ºC for 30 days. 
 
In vitro release study of GA  
The release study was performed using 12.000 
dalton pore size dialysis membrane for six hours.  
Two mL GA-loaded ME and MEg were placed in  
the dialysis bag. The dialysis bags were suspended in  
5 mL of distilled water and maintained at 37±0.5 °C 
with magnetic stirring at 400 rpm in a shaker  
(GFL 3032 Shaker, LABOTEC, Germany) during  
the experiment. At the end of six hours, the drug 
concentrations were analyzed by UV spectrophotometer 
and all experiments were performed in triplicate. 
 
Cell culture studies 
L929 cells were grown in a medium composed of 
EMEM containing 25 mM glucose, 5 mM glutamine 
supplemented with 10% horse serum, 1% gentamicin, 
and 7.5% sodium bicarbonate in an incubator at 37 ºC 
under 5% CO2 atmosphere. The medium was changed 
with fresh EMEM every 48 hours. The presence of a 




Cell viability on L929 cells was evaluated using the 
MTT test. In the test, L929 cells were seeded (10.000 
cells/well) in 96-well culture plates16. Plates were kept 
at 37 ºC for 24 hours for cell adhering. Then, the cells 
were treated with different GA concentrations (62.5-
1000 µg/mL), blank and GA loaded MEs and MEgs. 
After six hours, the medium was removed and 100 µL 
fresh medium and 13 µL MTT solution (5 mg/mL in 
phosphate-buffered saline) were added. After 
incubation for 4 hours at 37 °C, 100 μL of DMSO 
was added to each well to dissolve the formazan 
precipitate. The colour density was measured at  
570 nm with a multi-well ELISA reader (Biotech 
Synergy HT, USA)17. The wells containing only the 
medium were regarded as a control group with the 
cell viability of 100% and the results were presented 
as the percentage using the control group values. 
 
Transport experiments 
The L929 cells were seeded on Transwell® inserts 
which consist of an upper (apical) chamber, a porous 
permeable membrane where cells attach and form a 
tight monolayer, and a lower (basolateral) chamber18. 
Transport experiments were performed from the 
apical to the basolateral compartment, with samples 
collected from the basolateral compartment and the 
amount of GA at the end of the six-hours. 
 
Stability studies 
Stability studies were carried out with pH, ZP, DS 
and viscosity analysis of the samples after 30 days 
storage at 4 °C. Also, after the centrifugation, 
retention and freeze-thawing, stability of MEs was 
evaluated15 (Table 3). 
 
DPPH● and ABTS●+radicals scavenging activity 
The ability of the formulations to scavenge DPPH● 
was determined by the method of Gyamfi et al.19.  
A 50 µL aliquot of sample was mixed with 450 µL of 
Tris-HCl buffer (50 mM, pH 7.4) and 1.0 mL of  
0.1 mM DPPH● in MeOH. After 30 minutes of 
incubation in darkness and at ambient temperature, 
the resultant absorbance was recorded at 517 nm.  
The % inhibition was calculated using the following 
equation 
 
Inhibition % = [(Abscontrol – Abssample) / Abscontrol] x 100 
 
To further confirm the free radical scavenging 
activity of the formulations, an alternative synthetic 
radical ABTS●+ model was used, following the 
 
Table 3 — Stabilization of microemulsions after retention, freeze-thawing and centrifugation 
Formulation Retention Centrifugation Freeze-thawing 
F1 Not stable Not stable Not stable 
F2 Stable, monophasic Stable, monophasic Stable, monophasic 
F3 Not stable Not stable Not stable 
F4 Not stable Not stable Not stable 
F5 Stable, monophasic Stable, monophasic Stable, monophasic 
F6 Not stable Not stable Not stable 
 




method of Re et al.20. The ABTS●+ radical was 
generated by reacting a (7 mmol/L) ABTS●+ aqueous 
solution with K2S2O8 (2.45 mmol/L, final 
concentration) in the dark for 12-16 hours, at ambient 
temperature, and adjusting the absorbance 734 nm to 
0.700 with ethanol. After 990 µL ABTS●+ solution 
was added to 10 µL sample, the absorbance at 734 nm 
was recorded 1 minute after initial mixing and 
subsequently (for 30 minutes in total). The results are 
expressed as the Trolox equivalent antioxidant 
capacity (TEAC, mmol/L Trolox). Butylated hydroxyl 




All data in this study were considered as means±SD. 
One-way ANOVA was used for statistical analysis. 
GraphPad InStat ver. 2 was used for the analysis 
program. Significant differences between means were 




Analytical method and calibration 
For the detection of GA, the optimal wavelength of 
284 nm was found and the linearity plotting was 
(y=0.0246x+0.0156) (r2=0.997) for working solutions. 
 
Preparation of formulations 
The MEs produced by the titration method given  
in Table 1 generally had a transparent and 




For characterization of formulations, DSs and ZPs 
were measured and given in Table 2. The surface 
morphology of the F2 coded ME is shown in Fig. 2. 
 
Determination of the stability of MEs after retention, freeze-
thawing, and centrifugation 
The stability of MEs was determined according to 
the remain of the monophasic structure after retention, 
freeze-thawing and centrifugation (Table 3). 
 
Preparation and characterization of GA loaded MEs and 
MEgs 
F2 and F5 coded MEs were selected as the ideal 
formulations considering stability, DS and ZP. GA-
loaded F2 and F5 coded MEs were prepared by 
adding GA at a concentration determined from the 
cytotoxicity test. The DS, ZP and pH of GA-loaded 
F2 and F5 formulations are shown in Table 4.  
The viscosities of F2 and F5 coded formulations 
were measured at different shear rate. The viscosity 
curves of the formulations are shown in Fig. 3. 
 
In vitro drug release studies 
In vitro release studies of GA-loaded ME and MEg 
were performed as described in the method section. 
After 6 hours, the samples were measured at 284 nm 
by UV spectrophotometer and cumulative drug 
release was calculated. At the end of the sixth hour, 
only 43.2% of the GA was released from the solution, 
while the released amount of GA % was found to be 
 
Fig. 2 — The physical appearance of F2 coded microemulsion. 
 
 
Fig. 3 — Rheology of gallic acid loaded microemulsions and 
microemulsion gels for F2 and F5 (n=3). 
 
Table 4 — Droplet size, zeta potential and pH of gallic  
acid-loaded F2 and F5 formulations 





F2 ME 1.04±0.02 -30.3±0.2 5.34±0.04 
F2 MEg 2.73±0.05 -26.8±0.4 5.04±0.03 
F5 ME 1.05±0.03 -37.2±0.2 5.32±0.01 
F5 MEg 3.29±0.07 -33.0±0.3 5.06±0.02 
Values are expressed as mean±standard deviation, n=3 
 




72.0 and 66.8% from F2 and F5 coded MEs, 
respectively. On the other hand, in F2 and F5 MEg, 
the released amount of GA was determined as 57.2 
and 43.0%, respectively. 
 
Cell viability 
The effects of GA solutions and ME formulation 
components were determined on the L929 cell 
viability for 6 hours using the MTT method. Cell 
viability of different concentrations of GA solutions 
and GA-loaded formulations is given in Fig. 4. 
 
Permeation studies 
The amount of transported GA form the L929 cell 
line was up to 41 and 27% for F2 and F5 ME, 
respectively. However, MEg formulations have 
limited the cell permeation of GA and it was found to 
be only 15 and 11% for F2 and F5 MEg, respectively. 
 
Stability studies 
The pH of F2 ME, which was kept at 4 ºC for  
30 days, was 5.22±0.03, while ZP was -26.7±0.2 mV, 
and DS was 1.60±0.03 µm (n=3). The viscosity curve 
of the formulations after stability studies is shown in 
Fig. 5. 
 
Antioxidant activity assay 
The released GA succeeded in scavenging DPPH● 
radicals at physiological pH values. As shown in 
Table 5, it was found that the ability of the released 
GA to scavenge DPPH● was determined and the 
percentage inhibition was found 52.79±1.29%. 
As can be seen in Fig. 6, the released GA manage 
to inhibit ABTS•+ radical in a time-dependent manner. 




Fig. 4 — Gallic acid solution with different concentrations,





Fig. 5 — Rheology of formulations after stability studies (n=3). 
 
 
Fig. 6 — ABTS●+  radical scavenging activity of the release GA 
for 30 min. 
 
Table 5 — Results of antioxidant activity of released gallic acid 
TEAC (mmol/L/Trolox) DPPH (% İnhibition) 
2.55±0.00 52.79±1.29 
Values are expressed as mean±standard deviation, n=3 
 
 





Thermodynamically stable MEs and MEgs are 
promising formulations for topical treatment that 
significantly increases drug absorption compared to 
solutions21. In the current study, stable ME and MEg 
formulations containing strong antioxidant GA were 
successfully developed and their characterizations and 
antioxidant activities were evaluated. 
Blank ME formulations were prepared using 
different ratios of oil:water:surfactant. Blank MEs 
were found to have DS between 1.0-2.1 µm and the 
ZP values between (-13.5) - (-35.7) mV (Table 2). 
The formulation with the smallest droplet size was  
the F2 which had the lowest fat and the highest 
surfactant ratio. 
The increase in ZP results in lower agglomeration 
of the droplets. Colloidal systems with a ZP value of 
greater than 30 mV and less than -30 mV are 
considered to be stable22. F2 and F5 formulations had 
the smallest DSs (1 and 1.2 µm) and appropriate ZPs 
(-33.6 mV and -35.7 mV) indicating that they were 
stable (Table 2). F2 and F5 coded MEs with low DS 
and ZP values close to -30 mV, were also found to 
maintain their homogenous, monophasic structures 
after retention, freeze-thawing and centrifugation 
(Table 3). Oil-in-water MEs which were miscible 
with water also maintained their homogeneous and 
monophasic phase structures after dilution with 
distilled water. F2 and F5 formulations have been 
identified as ideal formulations because they were 
stable with the smaller DS and appropriate ZP. 
Therefore, ME and MEg formulations containing GA 
have been prepared with F2 and F5 coded MEs. 
As can be seen in Table 4, the ZP values of F2  
and F5 coded ME and MEg formulations were close 
to -30 mV. While the DS of MEs was approximately 
1 µm, the DS of F2 and F5 MEg increased to 2.73 and 
3.29 1 µm, respectively (Table 4). The increase in the 
size of the droplets in the gels results from the higher 
viscosity of the gels. When the viscosities of the 
formulations were evaluated, there was no significant 
change in viscosity in F2 and F5 MEs and F2 and F5 
MEg (P >0.05). MEs behaved like a newtonian fluid, 
did not cause a change in the viscosity of MEs with 
the change of the shear rate. On the other hand, the 
MEg formulations behaved like a pseudoplastic fluid, 
displayed a decreasing viscosity with an increasing 
shear rate (Fig. 3). The pseudoplastic behaviour of 
MEg resulted from the pseudoplastic characterization 
of carbopol23. 
Skin pH is generally assumed to be between 5-6, 
however, there are also studies showing that the pH of 
the skin is below 5(ref 24). In our study, the pH of the 
formulations was in the range of 5-5.3, indicating that 
the formulations were also suitable for applying to the 
skin (Table 4). The F2 coded ME had an appropriate 
pH (5.3) for applying to the skin has been chosen as 
the ideal formulation. 
In the literature, ME based herbal formulations 
were prepared by using herbal medicines such as 
furocoumarin psoralen, curcumin, and triptolide for 
enhanced activity and reduced toxicity25-27. Although, 
no GA-loaded ME formulation was found in the 
literature. It is known that drug release can be  
altered by changing formulation parameters from 
MEs developed with different drugs28,29. In our  
study, it was also aimed to improve in vitro GA 
release by preparing ME formulation of GA. As 
expected, in vitro GA release was increased by 
loading GA into F2 and F5 coded MEs and F2  
coded MEg (P <0.05). In vitro GA release of F5 MEg 
and GA solution was similar (P >0.05). At the end  
of 6 hours, GA release was found to be 43.2% from 
GA solution and the amount of GA released increased 
to 72% in F2 ME and up to 66.8% in F5 ME. On the 
other hand, the in vitro GA release was determined as 
57.2 and 43.0% in F2 and F5 MEg, respectively. In 
MEs, in vitro GA release was greater. Due to the 
increase in viscosities and DSs of the MEg 
formulations led to decreased in vitro GA release 
according to ME (Fig. 2, Table 4). The reduction in 
the DS results in an increase in surface area and hence 
drug release. 
For cytotoxicity studies, we used the MTT test, 
which is the most commonly used. The effects of 
different concentrations of GA solution and MEs on 
L929 cell viability were investigated for 6 hours. 
According to the MTT test results, GA caused no 
cellular toxicity with the used dose in preparing MEs. 
Additionally, F2 and F5 coded MEs and MEgs were 
also not found to be toxic to cells, cell viability was 
over 80%. These high viability rates have shown that 
MEs can be used safely. 
Permeation studies were carried out for F2 and F5 
MEs and MEgs through L929 cells. MEg 
formulations have limited the cell permeation of GA 
because of high viscosity and it was found to be only 
15 and 11% for F2 and F5 MEg, respectively. The 
amounts of GA were lower at permeation study than 
release study. The reason for this is that it has been 




interpreted as tight junction regions in the cell layer 
and in particular, a high viscosity in MEg 
formulations. In the literature, to the authors’ 
knowledge, there is no data to compare our results, so 
this is the first study of MEs containing GA as a 
bioactive molecule. 
pH, ZP, DS and viscosity of F2 ME did not  
change at 4 °C for 30 days. After stability studies,  
the pH of F2 ME was 5.22 and still between 5-5.3.  
ZP value decreased to -26.7 from -30.3 mV. The fact 
that the ZP was still close to -30 mV after stability 
studies proved that the F2 coded ME maintained  
its stability at 4 ºC for 30 days. Although DS of  
F2 ME increased to 1.6 from 1.04 µm after 30 days  
at 4 °C, it had an acceptable DS. As can be seen in 
viscosity results, viscosity changed in all formulations 
except F2 ME after stability studies. The viscosity at 
50 rpm of F2 and F5 MEg was increased to 102 and 
109 cP from 94 and 95 cP, respectively. While 
viscosity of F5 ME was increased to 77 from 38 cP  
(P <0.05), the increase in F2 ME was only to 84 from 
78 cP at 50 rpm. The minimum change in the 
viscosity, which was not statistically significant, was 
observed in F2 ME (P >0.05). So all the stability 
studies showed that F2 coded ME was stable at 4 °C 
for 30 days. 
Removal of harmful and pathogenic radicals from 
the body is very important. For this purpose, in the 
measurement of the antiradical effects of the samples, 
nitrogen-based stable radical, DPPH● radical and a 
blue/green coloured ABTS+● radical cation were used. 
As a result of studies conducted with the release 
sample, the cleansing effect of GA on the 
physiological pH of DPPH radicals was higher than 
50% (Table 5). The TEAC analysis is based on the 
inhibition of ABTS radical cation absorbance by 
antioxidants. As shown in Fig. 6, the released GA 
exhibited strong antioxidant activity by almost 
bleaching the entire radical. It was concluded that the 
prolonged potent antiradical activity could be 
sustained for 6 hours. 
 
Conclusion 
As a result, it has been observed that novel MEs 
were successfully developed and the antioxidant 
effect of GA-loaded MEs has been found to be 
prolonged for 6 hours. Also, these formulations were 
proposed for the field of cosmetics and topical 
application based on the strong antioxidant properties 
of GA. 
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